Practical implication
Stakeholders are advised to submit comments on the draft guidance by 11/18/2026, using docket number FDA-2026-D-8561 to ensure FDA considers their feedback before finalizing the document.
The FDA has issued draft guidance titled 'Potency Assessment of Active Immunotherapy Products,' intended for comment, outlining recommendations for developing assays to assess potency in active immunotherapy products (ACTIMPs). While non-binding and not yet for implementation, the document suggests that potency assay requirements may alter current compliance processes in regulatory practices for ACTIMPs.
What changed: The FDA introduced draft guidance recommending new strategies for potency assessment of active immunotherapy products, which includes specific assay development needs to ensure potency assurance.
Why it matters: This guidance reflects the FDA’s current thinking and may significantly shape how potency is managed and assessed in biologic applications, impacting regulatory compliance and product development strategies.
Practical implication: Stakeholders are advised to submit comments on the draft guidance by 11/18/2026, using docket number FDA-2026-D-8561 to ensure FDA considers their feedback before finalizing the document.
View original source
- Source: FDA - Regulatory Information
- Published at source: 2026-08-25T11:00:00.000Z
- Discovered by monitor: 2026-08-26T23:38:58.860Z
Published from the regulator source ingestion pipeline after PV impact triage.
